Semi-Annual Consolidated Statement Of Comprehensive Income

ASKA Pharmaceutical Holdings CO., Ltd. - Filing #7539685

Concept 2023-04-01 to
2023-09-30
2022-04-01 to
2022-09-30
Semi-annual consolidated statement of comprehensive income
Statement of comprehensive income
Profit (loss)
4,129,000,000 JPY
2,346,000,000 JPY
Other comprehensive income
Valuation difference on available-for-sale securities
-134,000,000 JPY
519,000,000 JPY
Remeasurements of defined benefit plans, net of tax
-15,000,000 JPY
13,000,000 JPY
Share of other comprehensive income of entities accounted for using equity method
271,000,000 JPY
371,000,000 JPY
Other comprehensive income
121,000,000 JPY
905,000,000 JPY
Comprehensive income
4,251,000,000 JPY
3,251,000,000 JPY
Comprehensive income attributable to
Comprehensive income attributable to owners of parent
4,251,000,000 JPY
3,251,000,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.